Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you may recall, our treasured signal to daydream about weekend plans. Our agenda is quite modest. We hope to catch up on our reading, take a few naps, promenade with the official mascots and take a few more naps. And what about you? This may be a good time to tidy up around your castle or take in a moving picture show or two. You could reach out to someone special or maybe plan a getaway. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The Novartis (NVS) bribery scandal case that is causing a political ruckus in Greece may be returned to prosecutors, Ekathimerini reports. The parliament agreed to probe 10 politicians for allegedly accepting or facilitating bribes from the drug maker, which purportedly sought to boost sales of its medicines. But there may be two key problems with the case: a lack of evidence to substantiate the claims of protected witnesses and the fact that some of the alleged offenses have expired under the statute of limitations. Novartis has denied the allegations.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.